Global RNAi Drugs Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

According to our (Global Info Research) latest study, the global RNAi Drugs market size was valued at US$ 103090 million in 2024 and is forecast to a readjusted size of USD 383900 million by 2031 with a CAGR of 20.9% during review period.

It refers to the highly conservative, double stranded RNA induced, highly specific degradation of homologous mRNA in the evolutionary process

Increasing incidence of chronic medical and genetic disorders such as cancer and cardiovascular diseases (CVDs) across the globe is one of the key factors driving the market growth. Moreover, rising geriatric population, who are more susceptible to these diseases, is also driving the growth of the market. In line with this, as the coronavirus disease (COVID-19) continues to spread globally, the demand for RNAi drug delivery technology has also increased significantly. Targeted drug delivery approaches, such as aptamer delivery systems, are gaining enormous traction for the delivery of antiviral drugs because they are induced by small interfering RNA (siRNA) and can inhibit the expression of viral antigens. Furthermore, various technological advancements such as the development of innovative synthetic delivery vehicles and biological carriers are expected to drive the market growth. Nanocarriers, including siRNA or microRNA (miRNA), are crucial for the development of personalized medicine and the identification of altered cellular molecules and metabolites. Other factors, including extensive research and development (R&D) activities in nanotechnology and molecular diagnostics, and overall improvement in healthcare infrastructure are expected to further drive the market.

This report is a detailed and comprehensive analysis for global RNAi Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global RNAi Drugs market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031

Global RNAi Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031

Global RNAi Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031

Global RNAi Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for RNAi Drugs

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global RNAi Drugs market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Alnylam, Novo Nordisk, Eli Lilly, Alexion, Novartis, Roche, Arrowhead Pharmaceuticals Inc., CureVac AG, Dicerna Pharmaceuticals Inc., Gradalis Inc., etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

RNAi Drugs market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

siRNA

shRNA

Other

Market segment by Application

Hospital

Clinic

Other

Major players covered

Alnylam

Novo Nordisk

Eli Lilly

Alexion

Novartis

Roche

Arrowhead Pharmaceuticals Inc.

CureVac AG

Dicerna Pharmaceuticals Inc.

Gradalis Inc.

Ionis Pharmaceuticals Inc

Merck & Co. Inc.

Moderna Inc.

SBI ALApharma

Silence Therapeutics Plc

Sirnaomics Inc.

Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe RNAi Drugs product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of RNAi Drugs, with price, sales quantity, revenue, and global market share of RNAi Drugs from 2020 to 2025.

Chapter 3, the RNAi Drugs competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the RNAi Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and RNAi Drugs market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of RNAi Drugs.

Chapter 14 and 15, to describe RNAi Drugs sales channel, distributors, customers, research findings and conclusion.